ARTICLE | Company News
Biogen Idec seeks U.S. approval for hemophilia B therapy
January 5, 2013 12:35 AM UTC
Biogen Idec Inc. (NASDAQ:BIIB) submitted a BLA to FDA for rFIXFc to prevent and control hemophilia B in adults. The biotech and partner Swedish Orphan Biovitrum AB (SSE:SOBI) plan to submit an MAA to ...